Grant: Alliance Grants
McGill University
$107,660.00
Demonstrating technical and commercial advantages of mechanochemical synthesis for oligonucleotide production
EF 2024-25
Résumé
Oligonucleotide therapeutics have recently gained significant traction in the pharmaceutical industry due to their potential to treat or manage a wide range of diseases. However, challenges remain in the large-scale production of them due in part to the huge volumes of organic solvents required, which are toxic and costly to dispose of. Here, we focus on the use of Resonant Acoustic Mixing (RAM) for the synthesis of short oligonucleotide fragments, while reducing solvent consumption by 90% relative to traditional solution-phase reactions. The use of RAM has been developed in the Damha lab providing an efficient, cheap, and scalable process. The proposed research will build upon these development by optimizing reaction conditions and purification with an emphasis on further reducing the environmental impact. In collaboration with Cyclenium Pharma, the process will be scaled up and expanded to a range of nucleic acids with chemical modifications. The culmination of the project will be a Canadian first library of commercially available oligonucleotide fragments. This project will reduce both the cost and environmental impact of oligonucleotide synthesis, thereby enabling academic researchers and pharmaceutical companies to further develop life-saving therapies.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
596064-2024
Name nom
Damha, Masad MJ
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
107660
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Demonstrating technical and commercial advantages of mechanochemical synthesis for oligonucleotide production
Keywords
green chemistry; mechanochemistry; nucleic acid chemistry; oligonucleotide synthesis
Application summary
Oligonucleotide therapeutics have recently gained significant traction in the pharmaceutical industry due to their potential to treat or manage a wide range of diseases. However, challenges remain in the large-scale production of them due in part to the huge volumes of organic solvents required, which are toxic and costly to dispose of. Here, we focus on the use of Resonant Acoustic Mixing (RAM) for the synthesis of short oligonucleotide fragments, while reducing solvent consumption by 90% relative to traditional solution-phase reactions. The use of RAM has been developed in the Damha lab providing an efficient, cheap, and scalable process. The proposed research will build upon these development by optimizing reaction conditions and purification with an emphasis on further reducing the environmental impact. In collaboration with Cyclenium Pharma, the process will be scaled up and expanded to a range of nucleic acids with chemical modifications. The culmination of the project will be a Canadian first library of commercially available oligonucleotide fragments. This project will reduce both the cost and environmental impact of oligonucleotide synthesis, thereby enabling academic researchers and pharmaceutical companies to further develop life-saving therapies.